Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iradimed (IRMD) EBIT (2016 - 2025)

Historic EBIT for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $6.8 million.

  • Iradimed's EBIT rose 1804.47% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.9 million, marking a year-over-year increase of 1654.95%. This contributed to the annual value of $22.0 million for FY2024, which is 962.93% up from last year.
  • According to the latest figures from Q3 2025, Iradimed's EBIT is $6.8 million, which was up 1804.47% from $6.8 million recorded in Q2 2025.
  • Iradimed's 5-year EBIT high stood at $6.8 million for Q3 2025, and its period low was $1.8 million during Q1 2021.
  • In the last 5 years, Iradimed's EBIT had a median value of $4.7 million in 2024 and averaged $4.6 million.
  • Its EBIT has fluctuated over the past 5 years, first skyrocketed by 37764.07% in 2021, then crashed by 196.8% in 2024.
  • Iradimed's EBIT (Quarter) stood at $3.1 million in 2021, then skyrocketed by 36.8% to $4.3 million in 2022, then increased by 21.3% to $5.2 million in 2023, then rose by 12.41% to $5.8 million in 2024, then grew by 17.82% to $6.8 million in 2025.
  • Its EBIT stands at $6.8 million for Q3 2025, versus $6.8 million for Q2 2025 and $5.4 million for Q1 2025.